Wajgt A, Szczechowski L, Marczewska E, Grechuta M, Strzyzewska L, Gadomska B, Szyrocka-Szwed K
I Katedry i Kliniki Neurologii Sl. AM w Katowicach.
Neurol Neurochir Pol. 1988 May-Jun;22(3):188-94.
The aim of the reported study was an assessment of the effectiveness of high doses of methylprednisolone in the treatment of active exacerbation and its effect on the natural course of multiple sclerosis. The study was carried out on 24 patients with clinically certain disease, who were divided, according to the treatment given to them, into two subgroups: treated with methylprednisolone and treated with prednisone. The treatment was conducted by the double blind method. The statistical analysis of the results obtained in this material showed that in patients with acute and severe exacerbation of the disease methylprednisolone administration in high doses caused a rapid regression of paralysis and paresis and improved motor efficiency. However, an evaluation of the results after a year from treatment termination showed in both subgroups a progression of clinical changes and increased motor deficiency. This suggests that treatment with corticosteroids has no significant effect on the course of multiple sclerosis.
该报告研究的目的是评估高剂量甲基强的松龙治疗活动性病情加重的有效性及其对多发性硬化症自然病程的影响。该研究针对24例临床确诊的患者开展，根据给予他们的治疗方法，将其分为两个亚组：接受甲基强的松龙治疗的和接受泼尼松治疗的。治疗采用双盲法进行。对该材料中获得的结果进行统计分析表明，在病情急性严重加重的患者中，高剂量给予甲基强的松龙可使瘫痪和轻瘫迅速消退，并提高运动效率。然而，在治疗终止一年后对结果进行评估时发现，两个亚组的临床变化均有进展，运动功能缺陷增加。这表明用皮质类固醇治疗对多发性硬化症的病程没有显著影响。
